BIO's Comment on Advanced Notice of Proposed Rulemaking Regarding Review of Controls for Certain Emerging Technologies
January 17, 2019
BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S.’s global leadership in biotechnology, and pursue them “only to the extent necessary” to ensure national security, in accordance with the ECRA statement of policy for export controls in section 4811(1). Before proposing export controls on specific biotechnologies, the Commerce Department should assess the impact of each potential export control on the health of the biotechnology and life sciences ecosystem by evaluating the impact on domestic research, investment into U.S. companies developing or utilizing those technologies, and their ability to recruit and retain skilled talent necessary to develop or deploy those technologies.
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
The meeting of global trade ministers at the World Trade Organization’s 13th Ministerial Conference in Abu Dhabi offers an important opportunity to build on and strengthen the open and rules-based international trading system to support better…
BIO urges the Administration to fully assess the potential impact of export controls on biotechnologies on “the impact on the economy of the United States” and on the sustainability of the U.S.’s global leadership in biotechnology, and pursue them “only to the extent necessary” to ensure national security, in accordance with the ECRA statement of policy for export controls in section 4811(1). Before proposing export controls on specific biotechnologies, the Commerce Department should assess the impact of each potential export control on the health of the biotechnology and life sciences ecosystem by evaluating the impact on domestic research, investment into U.S. companies developing or utilizing those technologies, and their ability to recruit and retain skilled talent necessary to develop or deploy those technologies.